Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-493 and ABT-530 with or without ribavirin in DAA-experienced chronic hepatitis C
2015-002350-13Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of glecaprevir and ribavirin in chronic hepatitis C (CHC) (3 arms), sponsored by AbbVie Inc. Primary endpoints: SVR12 and safety. Started Oct 2015; status: completed.
02
Drugs
glecaprevirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2015-002350-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002350-13.